Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Inventory (2017 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Inventory for 9 consecutive years, with $52.0 million as the latest value for Q4 2025.

  • Quarterly Inventory rose 15.56% to $52.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $52.0 million through Dec 2025, up 15.56% year-over-year, with the annual reading at $52.0 million for FY2025, 15.56% up from the prior year.
  • Inventory for Q4 2025 was $52.0 million at Ultragenyx Pharmaceutical, roughly flat from $52.2 million in the prior quarter.
  • The five-year high for Inventory was $52.2 million in Q3 2025, with the low at $12.5 million in Q1 2021.
  • Average Inventory over 5 years is $31.4 million, with a median of $30.0 million recorded in 2023.
  • The sharpest move saw Inventory rose 5.08% in 2021, then skyrocketed 64.91% in 2022.
  • Over 5 years, Inventory stood at $16.2 million in 2021, then surged by 64.91% to $26.8 million in 2022, then grew by 26.91% to $34.0 million in 2023, then surged by 32.47% to $45.0 million in 2024, then grew by 15.56% to $52.0 million in 2025.
  • According to Business Quant data, Inventory over the past three periods came in at $52.0 million, $52.2 million, and $46.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.